β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology

Journal of Biological Chemistry

Volumn 288, Issue 36, 2013, Pages 26052-26066

  Ridley, Christina M ^a   Thur, Karen E ^a   Shanahan, Jessica ^a   Thillaiappan, Nagendra Babu ^b   Shen, Ann ^a   Uhl, Karly ^a   Walden, Charlotte M ^c   Rahim, Ahad A ^d   Waddington, Simon N ^d   Platt, Frances M ^b   Van Der Spoel, Aarnoud C ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONDURITOLS; GLUCOSIDASE; GLUCOSYLCERAMIDE; IMINOSUGARS;

BIOCHEMISTRY;

BIOLOGY;

BETA GLUCOSIDASE; BETA GLUCOSIDASE 2; CONDURITOL B EPOXIDE; GLUCOSYLCERAMIDASE; GLYCOSIDASE INHIBITOR; LUCERASTAT; MIGLUSTAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL;

CONDURITOL B EPOXIDE; ENZYME INHIBITORS; GLUCOSYLCERAMIDE; GLYCOLIPIDS; GLYCOSIDE HYDROLASES; MECHANISM-BASED ENZYME INHIBITOR; MEMBRANE LIPIDS; MIGLUSTAT; NONLYSOSOMAL GLUCOSYLCERAMIDASE; SPHINGOLIPID;

1-DEOXYNOJIRIMYCIN; ANIMALS; BETA-GLUCOSIDASE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CEREBELLAR ATAXIA; COS CELLS; ENZYME INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; INOSITOL; MICE; SPASTIC PARAPLEGIA, HEREDITARY;

EID: 84883662716     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.463562     Document Type: Article

References (94)

1. van Meer, G., Wolthoorn, J., and Degroote, S. (2003) The fate and function of glycosphingolipid glucosylceramide. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358, 869-873
2. Warnock, D. E., Lutz, M. S., Blackburn, W. A., Young, W. W., Jr., and Baenziger, J. U. (1994) Transport of newly synthesized glucosylceramide to the plasma membrane by a non-Golgi pathway. Proc. Natl. Acad. Sci. U.S.A. 91, 2708-2712
3. D'Angelo, G., Polishchuk, E., Di Tullio, G., Santoro, M., Di Campli, A., Godi, A., West, G., Bielawski, J., Chuang, C. C., van der Spoel, A. C., Platt, F. M., Hannun, Y. A., Polishchuk, R., Mattjus, P., and De Matteis, M. A. (2007) Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature 449, 62-67
4. Halter, D., Neumann, S., van Dijk, S. M., Wolthoorn, J., de Mazière, A. M., Vieira, O. V., Mattjus, P., Klumperman, J., van Meer, G., and Sprong, H. (2007) Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J. Cell Biol. 179, 101-115
5. Kolter, T., Proia, R. L., and Sandhoff, K. (2002) Combinatorial ganglioside biosynthesis. J. Biol. Chem. 277, 25859-25862
6. Hakomori, S.-I., and Ishizuka, I. (2006) in Glycolipids: Animal, eLS (Finazzi- Agrò, A., ed) John Wiley & Sons, Ltd., Chichester, UK
7. Kolter, T., and Sandhoff, K. (2005) Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu. Rev. Cell Dev. Biol. 21, 81-103
8. Boot, R. G., Verhoek, M., Donker-Koopman, W., Strijland, A., van Marle, J., Overkleeft, H. S., Wennekes, T., and Aerts, J. M. (2007) Identification of the non-lysosomal glucosylceramidase as -glucosidase J. Biol. Chem. 282, 1305-1312
9. Walden, C. M., Sandhoff, R., Chuang, C. C., Yildiz, Y., Butters, T. D., Dwek, R. A., Platt, F. M., and van der Spoel, A. C. (2007) Accumulation of glucosylceramide in murine testis, caused by inhibition of -glucosidase 2: implications for spermatogenesis. J. Biol. Chem. 282, 32655-32664
10. Yildiz, Y., Matern, H., Thompson, B., Allegood, J. C., Warren, R. L., Ramirez, D. M., Hammer, R. E., Hamra, F. K., Matern, S., and Russell, D. W. (2006) Mutation of-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J. Clin. Invest. 116, 2985-2994
11. Körschen, H. G., Yildiz, Y., Raju, D. N., Schonauer, S., Bönigk, W., Jansen, V., Kremmer, E., Kaupp, U. B., and Wachten, D. (2013) The non-lysosomal -glucosidaseGBA2is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi. J. Biol. Chem. 288, 3381-3393
12. Grabowski, G. A., and Beutler, E. (2000) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Sly, W. S., Childs, B., Beaudet, A. L., Valle, D., Kinzler, K. W., and Vogelstein, B., eds) 8th Ed., McGraw- Hill, New York
13. Martin, E., Schüle, R., Smets, K., Rastetter, A., Boukhris, A., Loureiro, J. L., Gonzalez, M. A., Mundwiller, E., Deconinck, T., Wessner, M., Jornea, L., Oteyza, A. C., Durr, A., Martin, J. J., Schöls, L., Mhiri, C., Lamari, F., Züchner, S., De Jonghe, P., Kabashi, E., Brice, A., and Stevanin, G. (2013) Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia. Am. J. Hum. Genet. 92, 238-244
14. Hammer, M. B., Eleuch-Fayache, G., Schottlaender, L. V., Nehdi, H., Gibbs, J. R., Arepalli, S. K., Chong, S. B., Hernandez, D. G., Sailer, A., Liu, G., Mistry, P. K., Cai, H., Shrader, G., Sassi, C., Bouhlal, Y., Houlden, H., Hentati, F., Amouri, R., and Singleton, A. B. (2013) Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity. Am. J. Hum. Genet. 92, 245-251
15. Sorli, S. C., Colié, S., Albinet, V., Dubrac, A., Touriol, C., Guilbaud, N., Bedia, C., Fabriàs, G., Casas, J., Ségui, B., Levade, T., and Andrieu-Abadie, N. (2013) The nonlysosomal -glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB J. 27, 489-498
16. Mullen, T. D., and Obeid, L. M. (2012) Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med. Chem. 12, 340-363
17. Gatt, S., and Dagan, A. (2012) Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids. Chem. Phys. Lipids 165, 462-474
18. Ponnusamy, S., Meyers-Needham, M., Senkal, C. E., Saddoughi, S. A., Sentelle, D., Selvam, S. P., Salas, A., and Ogretmen, B. (2010) Sphingolipids and cancer: ceramide and sphingosine 1-phosphate in the regulation of cell death and drug resistance. Future Oncol. 6, 1603-1624
19. Palma, C. D., and Perrotta, C. (2012) Ceramide as a target of chemotherapy: its role in apoptosis and autophagy. Clin. Lipidol. 7, 111-119
20. Bedia, C., Levade, T., and Codogno, P. (2011) Regulation of autophagy by sphingolipids. Anticancer Agents Med. Chem. 11, 844-853
21. Gouaze-Andersson, V., and Cabot, M. C. (2011) Sphingolipid metabolism and drug resistance in hematological malignancies. Anticancer Agents Med. Chem. 11, 891-903
22. Messner, M. C., and Cabot, M. C. (2010) Glucosylceramide in humans. Adv. Exp. Med. Biol. 688, 156-164
23. Ardes-Guisot, N., Alonzi, D. S., Reinkensmeier, G., Butters, T. D., Norez, C., Becq, F., Shimada, Y., Nakagawa, S., Kato, A., Blériot, Y., Sollogoub, M., and Vauzeilles, B. (2011) Selection of the biological activity of DNJ neoglycoconjugates through click length variation of the side chain. Org. Biomol. Chem. 9, 5373-5388
24. Goddard-Borger, E. D., Tropak, M. B., Yonekawa, S., Tysoe, C., Mahuran, D. J., and Withers, S. G. (2012) Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease. J. Med. Chem. 55, 2737-2745
25. Wennekes, T., van den Berg, R. J., Donker, W., van der Marel, G. A., Strijland, A., Aerts, J. M., and Overkleeft, H. S. (2007) Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J. Org. Chem. 72, 1088-1097
26. Ghisaidoobe, A., Bikker, P., de Bruijn, A. C., Godschalk, F. D., Rogaar, E., Guijt, M. C., Hagens, P., Halma, J. M., van't Hart, S. M., Luitjens, S. B., van Rixel, V. H., Wijzenbroek, M., Zweegers, T., Donker-Koopman, W. E., Strijland, A., Boot, R., van der Marel, G., Overkleeft, H. S., Aerts, J. M., and van den Berg, R. J. (2010) Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars. ACS Med. Chem. Lett. 2, 119-123
27. Kallemeijn, W. W., Li, K. Y., Witte, M. D., Marques, A. R., Aten, J., Scheij, S., Jiang, J., Willems, L. I., Voorn-Brouwer, T. M., van Roomen, C. P., Ottenhoff, R., Boot, R. G., van den Elst, H., Walvoort, M. T., Florea, B. I., Codée, J. D., van der Marel, G. A., Aerts, J. M., and Overkleeft, H. S. (2012) Novel activity-based probes for broad-spectrum profiling of retaining -exoglucosidases in situ and in vivo. Angew. Chem. Int. Ed Engl. 51, 12529-12533
28. Lee, J. C., Francis, S., Dutta, D., Gupta, V., Yang, Y., Zhu, J. Y., Tash, J. S., Schönbrunn, E., and Georg, G. I. (2012) Synthesis and evaluation of eightand four-membered iminosugar analogues as inhibitors of testicular ceramide- specific glucosyltransferase, testicular -glucosidase 2, and other glycosidases. J. Org. Chem. 77, 3082-3098
29. Trapero, A., González-Bulnes, P., Butters, T. D., and Llebaria, A. (2012) Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating Gaucher disease. J. Med. Chem. 55, 4479-4488
30. Platt, F. M., and Jeyakumar, M. (2008) Substrate reduction therapy. Acta Paediatr. Suppl. 97, 88-93
31. Fantur, K., Hofer, D., Schitter, G., Steiner, A. J., Pabst, B. M., Wrodnigg, T. M., Stütz, A. E., and Paschke, E. (2010) DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts. Mol. Genet. Metab. 100, 262-268
32. Lieberman, R. L., D'aquino, J. A., Ringe, D., and Petsko, G. A. (2009) Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 48, 4816-4827
33. Sugawara, K., Tajima, Y., Kawashima, I., Tsukimura, T., Saito, S., Ohno, K., Iwamoto, K., Kobayashi, T., Itoh, K., and Sakuraba, H. (2009) Molecular interaction of imino sugars with human -galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Mol. Genet. Metab. 96, 233-238
34. Overkleeft, H. S., Renkema, G. H., Neele, J., Vianello, P., Hung, I. O., Strijland, A., van der Burg, A. M., Koomen, G. J., Pandit, U. K., and Aerts, J. M. (1998) Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J. Biol. Chem. 273, 26522-26527
35. Matern, H., Heinemann, H., Legler, G., and Matern, S. (1997) Purification and characterization of a microsomal bile acid -glucosidase from human liver. J. Biol. Chem. 272, 11261-11267
36. Platt, F. M., Neises, G. R., Karlsson, G. B., Dwek, R. A., and Butters, T. D. (1994) N-Butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J. Biol. Chem. 269, 27108-27114
37. Ashe, K. M., Bangari, D., Li, L., Cabrera-Salazar, M. A., Bercury, S. D., Nietupski, J. B., Cooper, C. G., Aerts, J. M., Lee, E. R., Copeland, D. P., Cheng, S. H., Scheule, R. K., and Marshall, J. (2011) Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLoS One 6, e21758
38. Nietupski, J. B., Pacheco, J. J., Chuang, W. L., Maratea, K., Li, L., Foley, J., Ashe, K. M., Cooper, C. G., Aerts, J. M., Copeland, D. P., Scheule, R. K., Cheng, S. H., and Marshall, J. (2012) Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-PickCmice. Mol. Genet. Metab. 105, 621-628
39. Platt, F. M., Reinkensmeier, G., Dwek, R. A., and Butters, T. D. (1997) Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J. Biol. Chem. 272, 19365-19372
40. Andersson, U., Butters, T. D., Dwek, R. A., and Platt, F. M. (2000) N Butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. 59, 821-829
41. Bijl, N., Sokolovic, M., Vrins, C., Langeveld, M., Moerland, P. D., Ottenhoff, R., van Roomen, C. P., Claessen, N., Boot, R. G., Aten, J., Groen, A. K., Aerts, J. M., and van Eijk, M. (2009) Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 50, 1431-1441
42. Aerts, J. M., Ottenhoff, R., Powlson, A. S., Grefhorst, A., van Eijk, M., Dubbelhuis, P. F., Aten, J., Kuipers, F., Serlie, M. J., Wennekes, T., Sethi, J. K., O'Rahilly, S., and Overkleeft, H. S. (2007) Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56, 1341-1349
43. Jeyakumar, M., Butters, T. D., Cortina-Borja, M., Hunnam, V., Proia, R. L., Perry, V. H., Dwek, R. A., and Platt, F. M. (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with Nbutyldeoxynojirimycin. Proc. Natl. Acad. Sci. U.S.A. 96, 6388-6393
44. Andersson, U., Smith, D., Jeyakumar, M., Butters, T. D., Borja, M. C., Dwek, R. A., and Platt, F. M. (2004) Improved outcome of N- butyldeoxygalactonojirimycin- mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol. Dis. 16, 506-515
45. Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., Proia, R. L., Winchester, B., Dwek, R. A., and Butters, T. D. (1997) Prevention of lysosomal storage in Tay-Sachs mice treated withN- butyldeoxynojirimycin. Science 276, 428-431
46. van der Spoel, A. C., Jeyakumar, M., Butters, T. D., Charlton, H. M., Moore, H. D., Dwek, R. A., and Platt, F. M. (2002) Reversible infertility in male mice following oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc. Natl. Acad. Sci. U.S.A. 99, 17173-17178
47. Walden, C. M., Butters, T. D., Dwek, R. A., Platt, F. M., and van der Spoel, A. C. (2006) Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin. Hum. Reprod. 21, 1309-1315
48. Bone, W., Walden, C. M., Fritsch, M., Voigtmann, U., Leifke, E., Gottwald, U., Boomkamp, S., Platt, F. M., and van der Spoel, A. C. (2007) The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study. Reprod. Biol. Endocrinol. 5, 1
49. Amory, J. K., Muller, C. H., Page, S. T., Leifke, E., Pagel, E. R., Bhandari, A., Subramanyam, B., Bone, W., Radlmaier, A., and Bremner, W. J. (2007) Miglustat has no apparent effect on spermatogenesis in normal men. Hum. Reprod. 22, 702-707
50. Smith, D., Wallom, K. L., Williams, I. M., Jeyakumar, M., and Platt, F. M. (2009) Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol. Dis. 36, 242-251
51. Stein, V. M., Crooks, A., Ding, W., Prociuk, M., O'Donnell, P., Bryan, C., Sikora, T., Dingemanse, J., Vanier, M. T., Walkley, S. U., and Vite, C. H. (2012) Miglustat improves Purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C. J. Neuropathol. Exp. Neurol. 71, 434-448
52. Pastores, G. M., Giraldo, P., Chérin, P., and Mehta, A. (2009) Goal-oriented therapy with miglustat in Gaucher disease. Curr. Med. Res. Opin. 25, 23-37
53. Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebícek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., Gow, I., Elstein, D., and Zimran, A. (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 1481-1485
54. Wraith, J. E., and Imrie, J. (2009) New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther. Clin. Risk. Manag. 5, 877-887
55. Patterson, M. C., Vecchio, D., Jacklin, E., Abel, L., Chadha-Boreham, H., Luzy, C., Giorgino, R., and Wraith, J. E. (2010) Long-term miglustat therapy in children with Niemann-Pick disease type C. J. Child. Neurol. 25, 300-305
56. Aerts, J. M., Boot, R. G., van Eijk, M., Groener, J., Bijl, N., Lombardo, E., Bietrix, F. M., Dekker, N., Groen, A. K., Ottenhoff, R., van Roomen, C., Aten, J., Serlie, M., Langeveld, M., Wennekes, T., and Overkleeft, H. S. (2011) Glycosphingolipids and insulin resistance. Adv. Exp. Med. Biol. 721, 99-119
57. Nash, R. J., Kato, A., Yu, C. Y., and Fleet, G. W. (2011) Iminosugars as therapeutic agents: recent advances and promising trends. Future Med. Chem. 3, 1513-1521
58. Asano, N. (2009) Sugar-mimicking glycosidase inhibitors: bioactivity and application. Cell. Mol. Life Sci. 66, 1479-1492
59. Horne, G., Wilson, F. X., Tinsley, J., Williams, D. H., and Storer, R. (2011) Iminosugars past, present and future: medicines for tomorrow. Drug Discov. Today 16, 107-118
60. Germain, D. P., and Fan, J. Q. (2009) Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies. Int. J. Clin. Pharmacol. Ther. 47, S111-S117
61. Parenti, G. (2009) Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med. 1, 268-279
62. van Weely, S., Brandsma, M., Strijland, A., Tager, J. M., and Aerts, J. M. (1993) Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta 1181, 55-62
63. Daniels, L. B., Glew, R. H., Diven, W. F., Lee, R. E., and Radin, N. S. (1981) An improved fluorometric leukocyte -glucosidase assay for Gaucher's disease. Clin. Chim. Acta 115, 369-375
64. Mumford, R. A., Raghavan, S. S., and Kanfer, J. N. (1976) Hydrolytic and transglucolytic activities of a partially purified calf brain -glucosidase. J. Neurochem. 27, 943-948
65. Premkumar, L., Sawkar, A. R., Boldin-Adamsky, S., Toker, L., Silman, I., Kelly, J. W., Futerman, A. H., and Sussman, J. L. (2005) X-ray structure of human acid-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J. Biol. Chem. 280, 23815-23819
66. Dinur, T., Osiecki, K. M., Legler, G., Gatt, S., Desnick, R. J., and Grabowski, G. A. (1986) Human acid -glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site. Proc. Natl. Acad. Sci. U.S.A. 83, 1660-1664
67. Grabowski, G. A., Osiecki-Newman, K., Dinur, T., Fabbro, D., Legler, G., Gatt, S., and Desnick, R. J. (1986) Human acid -glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes. J. Biol. Chem. 261, 8263-8269
68. Enquist, I. B., Lo Bianco, C., Ooka, A., Nilsson, E., Mansson, J. E., Ehinger, M., Richter, J., Brady, R. O., Kirik, D., and Karlsson, S. (2007) Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 104, 17483-17488
69. Kok, J. W., Eskelinen, S., Hoekstra, K., and Hoekstra, D. (1989) Salvage of glucosylceramide by recycling after internalization along the pathway of receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U.S.A. 86, 9896-9900
70. Gee, K. R., Sun, W. C., Bhalgat, M. K., Upson, R. H., Klaubert, D. H., Latham, K. A., and Haugland, R. P. (1999) Fluorogenic substrates based on fluorinated umbelliferones for continuous assays of phosphatases and -galactosidases. Anal. Biochem. 273, 41-48
71. Krippendorff, B. F., Neuhaus, R., Lienau, P., Reichel, A., and Huisinga, W. (2009) Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values. J. Biomol. Screen. 14, 913-923
72. Xu, Y. H., Ponce, E., Sun, Y., Leonova, T., Bove, K., Witte, D., and Grabowski, G. A. (1996) Turnover and distribution of intravenously administered mannose-terminated human acid-glucosidase in murine and human tissues. Pediatr. Res. 39, 313-322
73. Fink, J. K., Correll, P. H., Perry, L. K., Brady, R. O., and Karlsson, S. (1990) Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 87, 2334-2338
74. Chang, H. H., Asano, N., Ishii, S., Ichikawa, Y., and Fan, J. Q. (2006) Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J. 273, 4082-4092
75. Maegawa, G. H., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G. J., Hamuro, Y., Clarke, J. T., and Mahuran, D. J. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284, 23502-23516
76. Steet, R. A., Chung, S., Wustman, B., Powe, A., Do, H., and Kornfeld, S. A. (2006) The iminosugar isofagomine increases the activity of N370S mutant acid -glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl. Acad. Sci. U.S.A. 103, 13813-13818
77. Turner, B. M., Beratis, N. G., and Hirschhorn, K. (1977) Cell-specific differences in membrane -glucosidase from normal and Gaucher cells. Biochim. Biophys. Acta 480, 442-449
78. Wenger, D. A., Clark, C., Sattler, M., and Wharton, C. (1978) Synthetic substrate -glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher's disease. Clin. Genet. 13, 145-153
79. Ron, I., Dagan, A., Gatt, S., Pasmanik-Chor, M., and Horowitz, M. (2005) Use of fluorescent substrates for characterization of Gaucher disease mutations. Blood Cells Mol. Dis. 35, 57-65
80. McDonald, A. G., and Tipton, K. F. (2012) in Enzymes: Irreversible Inhibition, eLS (Finazzi-Agrò, A., ed) John Wiley & Sons, Ltd., Chichester, UK
81. Singh, J., Petter, R. C., Baillie, T. A., and Whitty, A. (2011) The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307-317
82. Newburg, D. S., Shea, T. B., Yatziv, S., Raghavan, S. S., and McCluer, R. H. (1988) Macrophages exposed in vitro to conduritol B epoxide resemble Gaucher cells. Exp. Mol. Pathol. 48, 317-323
83. Prence, E. M., Chaturvedi, P., and Newburg, D. S. (1996) In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology. J. Neurosci. Res. 43, 365-371
84. Wennekes, T., Meijer, A. J., Groen, A. K., Boot, R. G., Groener, J. E., van Eijk, M., Ottenhoff, R., Bijl, N., Ghauharali, K., Song, H., O'Shea, T. J., Liu, H., Yew, N., Copeland, D., van den Berg, R. J., van der Marel, G. A., Overkleeft, H. S., and Aerts, J. M. (2010) Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J. Med. Chem. 53, 689-698
85. Aureli, M., Bassi, R., Loberto, N., Regis, S., Prinetti, A., Chigorno, V., Aerts, J. M., Boot, R. G., Filocamo, M., and Sonnino, S. (2012) Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts. J. Inherit. Metab. Dis. 35, 1081-1091
86. Burke, D. G., Rahim, A. A., Waddington, S. N., Karlsson, S., Enquist, I., Bhatia, K., Mehta, A., Vellodi, A., and Heales, S. (2012) Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes. J. Inherit. Metab. Dis., in press
87. Gegg, M. E., Burke, D., Heales, S. J., Cooper, J. M., Hardy, J., Wood, N. W., and Schapira, A. H. (2012) Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 72, 455-463
88. Korkotian, E., Schwarz, A., Pelled, D., Schwarzmann, G., Segal, M., and Futerman, A. H. (1999) Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 274, 21673-21678
89. Trajkovic-Bodennec, S., Bodennec, J., and Futerman, A. H. (2004) Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes. Blood Cells Mol. Dis. 33, 77-82
90. Hein, L. K., Meikle, P. J., Hopwood, J. J., and Fuller, M. (2007) Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol. Genet. Metab. 92, 336-345
91. Marshall, J., McEachern, K. A., Kyros, J. A., Nietupski, J. B., Budzinski, T., Ziegler, R. J., Yew, N. S., Sullivan, J., Scaria, A., van Rooijen, N., Barranger, J. A., and Cheng, S. H. (2002) Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. Mol. Ther. 6, 179-189
92. Stephens, M. C., Bernatsky, A., Burachinsky, V., Legler, G., and Kanfer, J. N. (1978) The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects. J. Neurochem. 30, 1023-1027
93. Elleder, M. (2006) Glucosylceramide transfer from lysosomes-the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J. Inherit. Metab. Dis. 29, 707-715
94. Cantarel, B. L., Coutinho, P. M., Rancurel, C., Bernard, T., Lombard, V., and Henrissat, B. (2009) The Carbohydrate-active EnZymes database (CAZy): an expert resource for Glycogenomics. Nucleic Acids Res. 37, D233-D238